A Phase Ib open label, randomized, safety study of SANGUINATE™ in patients with sickle cell anemia

BACKGROUND: Treatment of sickle cell anemia is a challenging task and despite the well understood genetic and biochemical pathway of sickle hemoglobin, current therapy continues to be limited to the symptomatic treatment of pain, supplemental oxygen, antibiotics, red blood cell transfusions and hydr...

Descripción completa

Detalles Bibliográficos
Autores principales: Misra, Hemant, Bainbridge, James, Berryman, John, Abuchowski, Abraham, Galvez, Kenneth Mauricio, Uribe, Luis Fernando, Hernandez, Angel Luis, Sosa, Nestor Rodolfo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Hematologia e Hemoterapia 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339363/
https://www.ncbi.nlm.nih.gov/pubmed/28270341
http://dx.doi.org/10.1016/j.bjhh.2016.08.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339363/
https://www.ncbi.nlm.nih.gov/pubmed/28270341
http://dx.doi.org/10.1016/j.bjhh.2016.08.004

Ejemplares similares